Avalanche double-dip would double up

Ophthalmic gene therapy company Avalanche Biotechnologies Inc. (NASDAQ:AAVL) said it plans to raise up to $100 million in a follow-on underwritten by Jefferies; Cowen; Piper Jaffray; and William Blair.

Avalanche gained $10.99 (65%) to $27.09 in its first day of trading in July after raising $103 million through the sale of 6 million shares at $17 in an IPO (see BioCentury Extra, July 31). ...